Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2021.07.003
Abstract: OBJECTIVES To examine the budget impact of emicizumab as prophylactic therapy in reducing the frequency of bleeding episodes in patients with hemophilia A with inhibitors in Malaysia. METHODS A budget impact model was built to… read more here.
Keywords: bleeding episodes; budget impact; budget; prophylaxis ... See more keywords
Correlation analysis between frequency of gastrointestinal bleeding episodes and abnormal coagulation indexes in digestive system tumors
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-19012-8
Abstract: This retrospective observational analysis was conducted to explore the correlation between the frequency of bleeding in digestive system tumors and various coagulation indexes, providing clinical data for predicting multiple bleeding episodes in patients. A retrospective… read more here.
Keywords: correlation; coagulation indexes; system tumors; bleeding episodes ... See more keywords
Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2021.2004269
Abstract: Abstract Emicizumab has been widely used for prophylaxis in patients with hemophilia A (HA) of all ages, with or without factor VIII inhibitors. Data on emicizumab efficacy are certainly significant; however, protection against bleeding is… read more here.
Keywords: bleeding episodes; emicizumab prophylaxis; single center; breakthrough bleeding ... See more keywords
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14129
Abstract: The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA)… read more here.
Keywords: bleeding episodes; patients anti; prevention bleeding; anti fviii ... See more keywords